A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Trial Profile

A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Pentostatin (Primary) ; Anti-CD19 CAR-transduced T cells; Cyclophosphamide; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 26 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 18 May 2016 Results will be presented at the 2016 American Society of Clinical Oncology Annual Meeting, as per Juno Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top